# Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation

> **NCT00948753** · PHASE1,PHASE2 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 38 (actual)

## Conditions studied

- Graft-versus-host Disease
- Hematopoietic Stem Cell Transplantation

## Interventions

- **DRUG:** Maraviroc 150 MG
- **DRUG:** Maraviroc 300 mg
- **DRUG:** Maraviroc 300 mg Phase II

## Key facts

- **NCT ID:** NCT00948753
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2022-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00948753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00948753, "Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00948753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*